A new chimeric triple reporter fusion protein as a tool for in vitro and in vivo multimodal imaging to monitor the development of African trypanosomes and *Leishmania* parasites

Estefania Calvo-Alvarez, Christelle Cren-Travaillé, Aline Crouzols, Brice Rotureau

► To cite this version:

Estefania Calvo-Alvarez, Christelle Cren-Travaillé, Aline Crouzols, Brice Rotureau. A new chimeric triple reporter fusion protein as a tool for in vitro and in vivo multimodal imaging to monitor the development of African trypanosomes and *Leishmania* parasites. *Infection, Genetics and Evolution*, 2018, 10.1016/j.meegid.2018.01.011 . pasteur-01849818

HAL Id: pasteur-01849818

<https://hal-pasteur.archives-ouvertes.fr/pasteur-01849818>

Submitted on 3 Aug 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A new chimeric triple reporter fusion protein as a tool for *in vitro* and *in vivo* multimodal imaging to monitor the development of African trypanosomes and *Leishmania* parasites.

Estefania Calvo Alvarez*, Christelle Cren-Travaillé, Aline Crouzols and Brice Rotureau

Trypanosome Transmission Group, Trypanosome Cell Biology Unit, Institut Pasteur and INSERM U1201, Paris, France

* Corresponding author: Estefania Calvo Alvarez, estefania.calvo-alvarez@pasteur.fr

Key words: *Trypanosoma*, *Leishmania*, bioluminescence, fluorescence, intravital imaging, fusion protein, reporter.

Short title: A triple reporter for multimodal imaging of trypanosomatids

Number of figures: 8 (+3)

Highlights

- New triple reporter combining a red luciferase and a tdTomato fused by a Ty1-tag
- Tested in two different stages of both *T. brucei* and *L. major* parasites
- Tested *in vitro* and *in vivo* in tsetse flies and murine models
- Useful for multimodal imaging at different scales, including intravital monitoring

Abstract

Trypanosomiasis and leishmaniasis, caused by a group of related protist parasites, are Neglected Tropical Diseases currently threatening more than 500 million people worldwide. Reporter proteins have revolutionised the research on infectious diseases and have opened up new advances in the understanding of trypanosomatid-borne diseases in terms of both biology, pathogenesis and drug development. Here, we describe the generation and some applications of a new chimeric triple reporter fusion protein combining the red-shifted firefly luciferase PpyREH9 and the tdTomato red fluorescent protein, fused by the TY1 tag. Expressed in both *Trypanosoma brucei brucei* and *Leishmania major* transgenic parasites, this construct was successfully assessed on different state-of-the-art imaging technologies, at different scales ranging from whole organism to cellular level, both *in vitro* and *in vivo* in murine models. For *T. b. brucei*, the usefulness of this triple marker to monitor the entire parasite cycle in both tsetse flies and mice was further demonstrated. This stable reporter allows to qualitatively and quantitatively scrutinize in real-time several crucial aspects of the parasite's development, including the development of African trypanosomes in the dermis of the mammalian host. We briefly discuss developments in bio-imaging technologies and highlight how we could improve our understanding of parasitism by combining the genetic engineering of parasites to the one of the hosting organisms in which they complete their developmental program.

1. Introduction

Vector-borne diseases affect about half of the World's population and are endemic in more than 100 countries. Among these vector-borne diseases, trypanosomiasis and leishmaniasis are considered as important Neglected Tropical Diseases (NTDs) that especially impact public health, accounting for ~24 million persons infected worldwide among over 500 million people at risk. These diseases are (i) Human African Trypanosomiasis (HAT) or sleeping sickness that is caused by the African trypanosomes *Trypanosoma brucei* (Buscher et al., 2017; Franco et al., 2017), (ii) Chagas disease or American Trypanosomiasis that is due to the American trypanosome *Trypanosoma cruzi* (Perez-Molina and Molina, 2017; Stanaway and Roth, 2015), and (iii) leishmaniasis, a group of visceral and cutaneous diseases caused by a wide range of *Leishmania spp.* (Alvar et al., 2012; Matlashewski et al., 2014; Reithinger et al., 2007). In addition, some other trypanosome species (mainly *T. evansi*, *T. equiperdum*, *T. congolense* and *T. vivax*) cause similar diseases in domestic animals and are responsible for important economic losses in developing countries (Rotureau and Van Den Abbeele, 2013). There is no vaccine against these parasites, most of the few currently available medications are not easily administrable and frequently present severe side effects, and drug resistance is dramatically increasing. However, in addition to mass screening and treatment programs, strategies for reservoir and / or vector control have proven their efficiency in certain endemic areas (Aksoy et al., 2017; Dias, 2015; Gonzalez et al., 2015).

In vivo intravital imaging methods have tremendously been improved over the last decades, and now represent powerful tools for the understanding of a large panel of dynamic biological processes, especially in the field of infectious diseases (Coombes and Robey, 2010). Beyond their obvious contribution to the ethical improvement of the experimental design of research studies on living animals, especially in terms of reduction and refinement, these approaches also offer a powerful and almost unbiased mean to monitor and compare the variable kinetics of infection among individuals. In the context of diagnostic tool and drug development, as well as in order to study the complex developmental cycles of trypanosomatid parasites, genetically engineered parasites have been developed to express a large panel of molecular reporters including fluorescent and bioluminescent probes both in *T. cruzi* (Lewis et al., 2015) and *T. brucei* (Burrell-Saward et al., 2015; Coles et al., 2017; MacLean et al., 2013; McLatchie et al., 2013; Van Reet et al., 2014), and especially in *Leishmania spp.* (Beattie and Kaye, 2011; Calvo-Alvarez et al., 2015a; Carneiro et al., 2017; Forestier, 2013; Lang et al., 2009; Taheri et al., 2015).

The choice of a given reporter is conditioned by that of a specific readout methodology that usually focuses on parasite detection at a single scale, *i.e.* at the cellular level in multi-well plates for drug screening, at the tissue level in *ex vivo* organ explants or models, at the entire

organism level to study the kinetics of the infection in lab animal models. However, only few attempts to combine these modes of detection and / or imaging have been proposed, especially in trypanosomatid research (Taheri et al., 2015). From the literature, dual reporter fusion proteins have been designed for the purpose of combining bioluminescence and fluorescence-based approaches: firefly luciferase Luc and EGFP (Patel et al., 2010; Taheri et al., 2015), firefly luciferase Luc2 and EGFP (Liu et al., 2010), firefly luciferase Luc2 and tdTomato (Liu et al., 2010), firefly luciferase Luc2 and TurboFP635 (Mezzanotte et al., 2014), mVenus and *Renilla* luciferase RLuc8, mTurquoise2 and RLuc8, mKusabiraOrange2 and RLuc8 (Takai et al., 2015). All these constructs encode for at least one marker emitting in the green. This is not optimal for intravital imaging due to the high absorption of the light at these wavelengths by the melanin and haemoglobin proteins present in tissues. To bypass this technical bias, McLatchie and colleagues have first reported a system that allows the detection of fewer than 100 bioluminescent *T. brucei* parasites in a murine model by the use of the codon-optimised red-shifted *Photinus pyralis* luciferase (PpyRE9H) (McLatchie et al., 2013). They were able to monitor in real time the parasite dissemination and to detect brain infections with a level of sensitivity *in vivo* that was significantly greater than achievable with a yellow firefly luciferase reporter (McLatchie et al., 2013). Almost at the same time, Van Reet *et al.* have compared the usefulness of three different red-shifted luciferases, and characterized their *in vitro* activity and growth profile, as well as their potential for *in vivo* murine infection follow-up in a set of diverse *T. brucei* strains (Van Reet et al., 2014). Burrell-Saward and co-workers also used the red bioluminescent *T. b. brucei* strain generated by McLatchie *et al.* to evaluate the efficacy of novel drugs *in vivo* against late-stage HAT and were able to detect drug relapse earlier than traditional methods (Burrell-Saward et al., 2015). In order to go a step further, we have selected and combined two reporters producing light in the red wavelengths (tdTomato at 581nm and red-shifted firefly luciferase PpyREH9 at 617nm) with a reduced absorption in tissues, therefore resulting in an enhanced sensitivity of the monitoring.

Common protocols, such as for electron microscopy, histology or protein biochemistry, can require deleterious heat and / or chemical treatments of the samples that frequently result in a denaturation of these recombinant proteins preventing further fluorescent emission, enzymatic activities as well as immuno-detection. To circumvent these obstacles, the Ty1 epitope has become a popular choice in trypanosomes, but also in other parasites such as *Leishmania* and *Toxoplasma* (Bastin et al., 1996). The Ty-tag is a 10-amino-acid sequence from the immunologically well-characterized major structural protein of the Ty1 virus-like particle of *Saccharomyces cerevisiae* (Brookman et al., 1995). The epitope is recognized by two different monoclonal antibodies, BB2 (IgG1) and TYG5 (IgA), that were tested in a variety of immunological conditions and that do not cross-react with trypanosome proteins.

Although a number of commercial antibodies from various companies are available against either firefly luciferase or tdTomato, the Ty1-tag has been used extensively in Trypanosomatids and it has already proved its usefulness in multiple contexts (Huet et al., 2014; Julkowska and Bastin, 2009; Ooi et al., 2015). Therefore, between the two red-emitting probes, we have inserted a small Ty1-tag (Bastin et al., 1996) that can be detected in most of conditions, in order to obtain a stable cytosolic triple marker fusion protein (PpyRE9H/TY1/tdTomato) that can be used to study the same sample by multi-modal detection and imaging approaches.

Here, we describe the generation of this new chimeric triple reporter fusion protein. This construct was successfully assessed on state-of-the-art imaging technologies both *in vitro* and *in vivo* by using *Trypanosoma brucei* and *Leishmania major* transgenic parasites. This approach allowed us to scrutinize the development of both parasites within the mammalian host, as well as the journey of African trypanosomes in the tsetse fly digestive tract.

2. Material and methods

2.1 *Leishmania major* and *Trypanosoma brucei brucei* strains and culture

The AnTat 1.1E pleomorphic clone of *Trypanosoma brucei brucei* was derived from a strain originally isolated from a bushbuck in Uganda in 1966 (Le Ray et al., 1977). Procyclic forms (PCF) were grown at 27°C in SDM-79 medium (Brun and Schonenberger, 1979) supplemented with 10% (v/v) heat-inactivated foetal calf serum (FCS) and 8 mM glycerol (SDMG). Bloodstream forms (BSF) of the same strain were cultivated in complete HMI-11 medium (Kooy et al., 1989) at 37°C in 5% CO₂. For *in vitro* slender to stumpy BSF differentiation, we used 8-pCPT-2'-O-Me-5'-AMP, a nucleotide analog of 5'-AMP from BIOLOG Life Science Institute (Germany). Briefly, 2x10⁶ pleomorphic AnTat 1.1E slender forms were incubated with 8-pCPT-2'-O-Me-5'-AMP (5 µM) for 48 h (Barquilla et al., 2012). Freshly differentiated stumpy forms were then centrifuged and resuspended in SDMG medium with 10 mM glutathione for tsetse fly infection.

Leishmania major strain Friedlin V1 (MHOM/JL/80/Friedlin) (Kapler et al., 1990), was cultured at 26°C in M199 supplemented with 25 mM HEPES pH 7.2, 0.1 mM adenine, 0.0005% (w/v) hemin, 2 µg/ml biotin, 0.0001% (w/v) biotin, 10% (v/v) FCS and antibiotic cocktail (50 U/ml penicillin, 50 µg/ml streptomycin).

2.2 Construction of the chimeric fusion DNA sequences

A 3.1 Kb sequence coding for the chimeric multiplex reporter protein PpyRE9H/TY1/tdTomato was genetically engineered. The resulting cytoplasmic reporter is composed of three distinct markers: the red-shifted luciferase (PpyRE9H) is fused to the tdTomato red fluorescent protein by a Ty1 tag.

To generate RED *T. brucei* parasites, the 1.68 Kb optimised version of the North American firefly *Photinus pyralis* luciferase (Branchini et al., 2005) was fused with a 30-bp sequence known as Ty1-tag (Bastin et al., 1996) and cloned into the pTSARib plasmid (Xong et al., 1998) by using *Xho*I and *Hind*III restriction enzymes to obtain the pTSARib-PpyRE9H-TY1 plasmid. Finally, the 1.4 Kb coding region of the tdTomato fluorescent protein was inserted downstream using *Hind*III and *Bam*HI. The resulting 8.9 Kb pTSARib-PpyRE9H-TY1-tdTomato vector, containing a blasticidin S resistance cassette, was linearised with *Sph*I to integrate the rDNA promoter locus.

In order to generate the RED *L. major* strain, the same chimeric PpyRE9H/TY1/tdTomato protein coding sequence was amplified by PCR from the pTSARib-PpyRE9H-TY1-tdTomato vector. PCR product was cut with *Bgl*II and *Not*I restriction enzymes and ligated into the same sites of the pLEXSY-hyg2 expression vector (Jena Bioscience GmbH, Germany).

2.3 Generation of the RED parasites

Parasites genetically engineered to express the chimeric multiplex reporter protein PpyRE9H/TY1/tdTomato in their cytosol will be further referred as RED strains.

Trypanosomes BSF and PCF were transformed with an Amaxa Nucleofector (Lonza) (Burkard et al., 2007; MacGregor et al., 2013) and sub-cloned by limiting dilution. Clone selection was performed by measuring both bioluminescence in a microplate reader Infinite® 200 (Tecan) and fluorescence with a Muse® cell Analyzer (Merck-Millipore). Cells were routinely counted with an automated Muse® cell Analyzer (Merck-Millipore) and / or manually with a KOVA hemocytometer according to the manufacturer's recommendations.

L. major promastigote parasites were transformed with the large Swal targeting fragment derived from the final 11.1 Kb pLEXSY-PpyRE9H-TY1-tdTomato plasmid by electroporation and subsequent plating on semisolid media containing 200 µg/ml hygromycin B as previously described (Kapler et al., 1990). The fluorescent and bioluminescent clones were confirmed by using a microplate reader Infinite® 200 (Tecan) and a Muse® cell Analyzer (Merck-Millipore).

2.4 In vitro fluorescence and bioluminescence quantification in RED parasites

To perform the parasite density / fluorescence-bioluminescence intensity assay with the RED PCF and BSF trypanosomes, as well as with promastigotes of the RED *L. major* strain, parasites were counted, centrifuged and resuspended in fresh SDM-G, HMI-11 and M199 medium, respectively. Then, 100µl (or 10⁷ parasites) of this suspension were transferred into black clear-bottom 96-well plates and serial 2-fold dilutions were performed in triplicate adjusting the final volume to 200µl with 300 µg/ml of beetle luciferin (Promega, France). Luciferase activity was quantified after 10 minutes of incubation with a microplate reader Infinite® 200 (Tecan) or an IVIS® Spectrum imager (Perkin Elmer), following the instructions of the Promega Luciferase Assay System. After removal of intensity values from parasite-free medium corresponding to the background noise, results were analyzed as mean ±SD of three independent experiments.

2.5 Tsetse fly maintenance, infection by RED *Trypanosoma brucei brucei* and dissection

Glossina morsitans morsitans tsetse flies were maintained in Roubaud cages at 24°C and 60% hygrometry and fed through a silicone membrane with fresh mechanically defibrinated sheep blood. Teneral males (between 24h and 72h post-emergence) were allowed to ingest parasites in culture medium during their first meal through a silicone membrane. Here, we used either (i) cultured PCF trypanosomes at 5x10⁶ cells per millilitre in SDM79 medium supplemented with 10% foetal bovine serum, 8mM glycerol and 10mM glutathione (MacLeod

et al., 2007), or (ii) freshly *in vitro* differentiated stumpy BSF trypanosomes resuspended at 2×10^6 cells per millilitre in SDMG medium supplemented with 10mM glutathione (MacLeod et al., 2007).

Flies were starved for at least 24 hours before being dissected. After rapid isolation of the salivary glands in a drop of phosphate buffer saline (PBS), whole tsetse alimentary tracts, from the distal part of the foregut to the malpighian tubules, were dissected and arranged lengthways in a another drop of PBS as previously described (Rotureau et al., 2011; Rotureau et al., 2012). Isolated organs were then either scrutinized under a microscope at high magnification and imaged, or individually dilacerated, dried on the slide and further treated for immuno-fluorescence (Rotureau et al., 2014).

Salivation tests were performed one month after the infective meal. First, cold-anesthetized flies were rapidly screened for the presence of a red fluorescent signal through the cuticle of their ventral abdomen under an epifluorescence M165FC stereomicroscope (Leica) at the 10x magnification. Positive flies were sorted, starved for 48h, and individual flies were allowed to probe on warm clean glass slides for 5 minutes. Saliva drops were eventually checked for the presence of fluorescent metacyclic trypanosomes under a DMIL LED epifluorescence microscope (Leica) at the x60 magnification.

2.6 Mouse strains and ethical statements

Wild type BALB/c and C57BL/6J mice from Janvier Laboratory were used as models for experimental infection and monitoring of the bioluminescence with IVIS Spectrum and IVIS CT. In addition, to allow for further 3D intravital imaging of the lymphatic and blood systems, C57BL/6J-Flk1-EGFP mice expressing a GFP-tagged *Kdr* (*Flk1*) gene encoding the vascular endothelial growth factor receptor 2 (VEGFR-2), were also used (Ema et al., 2006). This study was conducted in strict accordance with the recommendations from the Guide for the Care and Use of Laboratory Animals of the European Union (European Directive 2010/63/UE) and the French Government. The protocol was approved by the "Comité d'éthique en expérimentation animale de l'Institut Pasteur" CETEA 89 (Permit number: 2012-0043 and 2016-0017) and undertaken in compliance with Institut Pasteur Biosafety Committee (protocol CHSCT 12.131). BR is authorized to perform experiments on vertebrate animals (license #A-75-2035) and is responsible for all the experiments conducted personally or under his supervision.

2.7 Mouse infections with RED parasites

RED BSF (10^5 parasites/mouse) were used to inoculate seven-week-old male C57BL/6J or BALB/c mice (Janvier, France) by the IP route. Parasitemia was assayed daily by automated fluorescent cell counting with a Muse cytometer (Merck-Millipore, detection limit at 5×10^2

parasites/ml) according to the manufacturer's recommendations. Alternatively, mice were infected via the natural route, i.e. by infective bites: tsetse flies with a mature salivary gland infection, assessed by a salivation test, were individually allowed to bite on the belly of a naïve mouse for about 15 minutes, and blood absorption was further verified by examination of their abdomen.

Seven-week-old male BALB/c mice were injected with 1×10^6 *L. major* PpyRE9H/TY1/tcTomato stationary-phase promastigotes (4 to 5-day old) in the hind footpads. After 4 weeks, animals were euthanized by cervical dislocation and popliteal lymph nodes were dissected for imaging. The total number of living parasites invading the target organs (popliteal lymph node draining the injected site) was calculated from serially-diluted single-cell suspensions and dispensed into 96-well plates. Parasitic load expressed as Limiting Dilution Assay Units (LDAU) after ten days of differentiation of amastigotes into promastigotes. The number of parasites was calculated as follows: Limit Dilution Assay Units (LDAU) = (geometric mean of titre from quadruplicate cultures) x (reciprocal fraction of the homogenized organ added to the first well). The titre was the reciprocal of the last dilution in which parasites were observed (Lima et al., 1997).

2.8 Ex vivo fluorescence imaging of RED parasites

For live fluorescence imaging of *Leishmania* promastigotes and all trypanosome stages, parasites in blood, in culture medium or isolated from tsetse fly midgut were observed either (i) with a DMI4000 microscope (Leica) and images were acquired with a Retiga-SRV camera (Q-Imaging), or (ii) with a DMIL LED microscope (Leica) and images were acquired with a digital color DFC450 C camera (Leica). Trypanosomes in tsetse organs were directly monitored with a M165FC stereomicroscope (Leica) with a monochromatic DFC30000 G camera (Leica). For intracellular *Leishmania* amastigote observations, peritoneal macrophages were collected from one BALB/c mouse. Then, 5×10^5 cells were plated on Ibidi chambers and infected at a ratio of 10 stationary-phase promastigotes per macrophage as previously described, and maintained for 72h at 37°C in 5% CO₂ (Spath et al., 2000). Intracellular amastigotes were then observed with a DMI4000 microscope (Leica) and images were acquired with a Retiga-SRV camera (Q-Imaging). For figure preparation, specific ROI were selected and fluorescent frames were normalized to the same scale of intensity with ImageJ (NIH).

2.9 In vivo fluorescence imaging of RED parasites

RED trypanosomes were monitored in the ear of Kdr (Flk1) C57BL/6J Rj mice by spinning-disk confocal microscopy as described previously (Capewell et al., 2016). Briefly, mice were first anaesthetised by IP injection of ketamine (Imalgene 1000 at 125 mg/kg) and xylazine

(Rompun 2% at 12.5 mg/kg). Mice were wrapped in a heating blanket and placed on an aluminium platform with a central round opening of 21 mm in diameter. A coverslip was taped on the central hole and the mouse was positioned so that the ear was lying on this oiled coverslip. Imaging was performed using an UltraView ERS spinning-disk confocal system (Perkin Elmer) with a x40 oil objective (1.3 numerical aperture). Movies were acquired by an EM-CCD camera (Hamamatsu) controlled by the Volocity software (Perkin Elmer) with an exposure time of 500 ms for a total of 30 to 120 s. Images were analysed using ImageJ 1.48v and its plugin Bio-formats importer (NIH).

2.10 In vivo bioluminescence imaging of RED parasites

Infection by bioluminescent parasites was monitored daily by detecting the bioluminescence in whole animals with the IVIS® Spectrum imager (Perkin Elmer). The equipment consists of a cooled charge-coupled camera mounted on a light-tight chamber with a nose cone delivery device to keep the mice anaesthetized during image acquisition with 1.5% isoflurane. D-luciferin potassium salt (Promega) stock solution was prepared in PBS at 33.33 mg/ml, filter-sterilized and stored in a -20°C freezer. To produce bioluminescence, mice were inoculated IP with 150 µl of D-luciferin stock solution (250mg/kg). After 10 minutes of incubation to allow substrate dissemination, all mice were anaesthetized in an oxygen-rich induction chamber with 2% isoflurane, and images were acquired by using automatic exposure (30 seconds to 5 minutes) depending on signal intensity. Images were analyzed with Living Image software version 4.3.1 (Perkin Elmer). Data were expressed in average radiance (p/s/cm²/sr) corresponding to the total flux of bioluminescent signal according to the selected area (total body of the mouse here). The background noise was removed by subtracting the bioluminescent / fluorescent signal of the control mouse from the infected ones for each acquisition.

Morphological / anatomical imaging technologies, such as computed tomography (CT) can be used to provide a combination of functional and anatomical data ensuring that maximum information is extracted from the infected animal model (Willmann et al., 2008). Longitudinal imaging is also used in pre-clinical studies to follow the progress of a disease or measure the effect of a therapeutic (Lim et al., 2011). Bioluminescence was acquired with a cooled CCD camera using the IVIS® Spectrum CT scanner (Perkin Elmer). Each animal was injected with 150 mg/kg of D-luciferin IP 10 min prior to imaging. Six spectrally resolved images were acquired using emission filters at 560, 580, 600, 620, 640, and 660 nm with a bandwidth of 20 nm each and an exposure time of 180 seconds. 3D tomographic reconstruction and superposition over the CT volume was performed using the DLIT algorithm available in the Living Image software 4.3. (Perkin Elmer), which uses single-view multispectral bioluminescence images to perform the reconstruction with segmentation of the CT images

in order to provide the mouse body boundary. The bioluminescence signal emitted by RED AnTat 1.1E parasites was monitored 4 days after the inoculation of 10^5 BSF by IP route in BALB/c mice.

2.11 Immuno-fluorescence analysis and immuno-histology

For immuno-histology, samples from the most bioluminescent skin regions were fixed in 4% paraformaldehyde over-night, processed into paraffin blocks and trimmed. Sections were processed for immuno-histochemical staining as described above. For immuno-fluorescence, parasites were settled on poly-L-lysine coated slides and fixed in methanol at -20°C for 5 seconds and re-hydrated in PBS for 10 minutes. Slides were incubated with the BB2 primary antibody diluted in PBS containing 0.1 % bovine serum albumin for 45 minutes at 37°C . The BB2 monoclonal antibody targets the Ty1-tag (mouse IgG1, up to 1/10) (Bastin et al., 1996). Slides were then washed and incubated with an anti-mouse-IgG1 secondary antibody coupled to Cy3 (Jackson) for 30 minutes at 37°C . Slides were finally stained with 4',6-diamidino-2-phenylindole (DAPI) for visualization of kinetoplast and nuclear DNA content, and mounted under cover slips with ProLong antifade reagent (Invitrogen), as previously described (Rotureau et al., 2011). Samples were observed either with a DMR microscope (Leica) and images were captured with a CoolSnap HQ camera (Roper Scientific), or with a DMI4000B microscope (Leica) and images were acquired with an ORCA-03G camera (Hamamatsu). Image acquisition was controlled using Micro-manager (NIH) and images were taken with the min/max threshold set at maximum.

2.12 Western blotting

For western blotting, samples were prepared by washing cells in serum-free medium before dilution with PBS and boiling in Laemmli for 5 minutes. SDS-PAGE separation was carried out after loading 10, 1 and 0.1 μg of total proteins per lane (corresponding to 10^6 , 10^5 and 10^4 cells, respectively). Proteins were transferred onto polyvinylidene fluoride membranes for 7 minutes by using the Trans-Blot[®] Turbo[™] technology (Bio-Rad), and blocked with 5% skimmed milk in PBS with 0.1% Tween 20 for 1 h prior to probing. The following primary antibodies were used by dilution in 2% milk in PBS with 0.1% Tween 20: L8C4 (non-diluted) (Kohl et al., 1999) and BB2 (1:50) (Bastin et al., 1996). Anti-mouse horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences) were used at a 1:20,000 dilution. Membranes were washed in PBS with 0.1% Tween 20 after blocking, between probing with primary and secondary antibodies and prior to band detection by chemiluminescence (GE healthcare).

2.13 Measurements, normalization and statistical analysis

Normalization of signals was carried out by parallel manipulation of min/max signals in ImageJ (NIH). For clarity purposes, brightness and contrast of several pictures were adjusted after their analysis in accordance with editorial policies. Statistical analyses and plots were performed with XLSTAT 2015.4.01 (Addinsoft) and Excel 2011 (Microsoft), respectively. Statistical analyses include linear regression analyses for bioluminescence / fluorescence intensity Vs. parasite density, ANOVA for growth curves, and ANCOVA for fly infection rates, with Tukey ad-hoc post-tests for inter-group comparison, all with 95% confidence.

3. Results

We have generated a new chimeric triple reporter recombinant protein of 1,036 aa named PpyRE9H/TY1/tdTomato and composed by the fusion of (i) the human codon-optimized red-shifted version of the North American firefly *Photinus pyralis* luciferase (Branchini et al., 2005), (ii) a short amino acid sequence known as Ty1-tag (Bastin et al., 1996), and (iii) the tdTomato fluorescent protein (Fig. S1).

During the plasmid-construct amplification in *E. coli* DH5 α , the fusion protein expression was attested by the red colour of bacterial pellets and further confirmed under an epifluorescence microscope, demonstrating the potential usefulness of this construct also in prokaryotic cells. The triple reporter construct was then expressed in the cytoplasm of the eukaryotic protist parasites *Leishmania major* and *Trypanosoma brucei brucei*. These strains will be further referred to as the RED parasites in the entire article.

3.1 *In vitro* and *in vivo* applications with RED *L. major* parasites

In order to explore the usefulness of the novel triple reporter construct, a transgenic *Leishmania major* strain expressing the PpyRE9H/TY1/tdTomato was generated. Promastigotes of *L. major* Friedlin reference strain were electroporated and selected in semi-solid plates to obtain single fluorescent and bioluminescent clones. The presence of the construct was checked by PCR on genomic DNA (Fig. S2A-B). Parasites were scrutinized under an epifluorescence microscope and their fluorescence was compared to that of wild type cells (WT) (Fig. 1A-B). A strong and specific red fluorescent signal was homogenously distributed in both the cytoplasm and the flagellum of RED promastigote cells only, but it was absent from their nucleus. The fluorescence of RED cells was further confirmed at the population level by flow cytometry analysis (Fig. 1C-D). Moreover, parasite proliferation *in vitro* was comparable to that of the parental cell line (Fig. 1E).

A linear correlation was found between the number of cells and the emission of bioluminescence, by measuring the signal *in vitro* in 96-well plates with an IVIS Spectrum imager (Fig. 2A), being able to detect as few as 10³ parasites (Fig. 2B). In parallel, this linear correlation was verified in a TECAN multiwell-plate reader for 5 RED sub-clones (Fig. 2C). Similarly, a linear correlation between the fluorescent signal intensity and the number of parasites was observed with both the imager (Fig. 2D), with a limit of detection at 10⁴ cells (Fig. 2E), and the plate reader for 5 RED sub-clones (Fig. 2F).

To test the efficiency of the RED *L. major* *in vivo*, the virulence of the transfected parasites was firstly recovered by passing the strain once through BALB/c mice. In order to determine whether RED *L. major* parasites could be detected *in vivo* using whole-body imaging, 10⁶ stationary-phase parasites were injected subcutaneously into the hind footpads of BALB/c

mice. Lesion progression was monitored both by the direct measurement of the bioluminescence (Fig. 3A) and fluorescence (Fig. 3B) emitted by RED amastigotes recorded in the IVIS Spectrum, and by the follow-up of the hind-limb lesions over four weeks (Fig. 3C-D). The bioluminescent signal start to increase from 5 days post-infection up to the end of the experiment, reaching a maximum radiance of 6.3×10^6 p/s/cm²/sr after four weeks of infection. However, *in vivo* follow-up of the fluorescence during the infection course showed that the fluorescent signal was visible only from the 3rd week after the infection, leading to the expected conclusion that bioluminescence was much more sensitive to evaluate the progression of infection in this context (Fig. 3C-D). After 29 days, mice were sacrificed and the popliteal lymph nodes were extracted and imaged (Fig. 3E-F). Parasitic load (LDAU) in the popliteal lymph node draining the lesion of infected animals, determined by the limiting dilution method, was 4.8×10^6 as an average of both infected organs per mouse. These results are in accordance with regular parasitic load experiments. Then, *in vitro* infection was performed in freshly collected resident peritoneal macrophages in order to allow parasites to differentiate into intracellular amastigotes forms in which the expression of the triple marker was confirmed as assessed by the presence of a specific red fluorescent signal (Fig. S3A).

3.2 *In vitro* uses of RED *T. brucei* parasites

In order to explore the usefulness of the novel triple reporter construct in another trypanosomatid parasite, transgenic *Trypanosoma brucei brucei* mammalian bloodstream forms (BSF) and insect procyclic forms (PCF) were transformed with the pTSARib-PpyRE9H-TY1-tdTomato vector and immediately sub-cloned by limiting dilution. The presence of the construct was checked by PCR on genomic DNA (Fig. S2). RED PCF trypanosomes in culture were scrutinized under a fluorescence microscope for a direct visual confirmation of their fluorescent phenotype as compared to WT cells. As expected, the triple reporter was homogenously distributed in the cytoplasm, and in a lesser extend in the flagellum, only in transformed parasites, but it was absent from their nucleus (Fig. 4A-B). The fluorescence of RED cells was further confirmed at the population level by flow cytometry analysis (Fig. 4C-D). Similar observations were done with RED BSF trypanosomes, yet with a lower overall fluorescence intensity as compared to that in RED PCF cells (Fig. 4E-H). Although the proliferation of PCF was significantly slower in transformed parasites compared to WT cells (doubling time of 14.5 h and 10.5 h, respectively, ANOVA $p=0.034$) (Fig. 4I), the BSF proliferation rate *in vitro* was comparable to that of the parental cell line (doubling time of 6.5 h for both) (Fig. 4J). First, in order to verify the reliability of the bioluminescent marker as well as to define its detection threshold, a parasite density / bioluminescence intensity analysis was performed in

96-micro-well plates with an IVIS Spectrum imager (Fig. 5A-B). Parasite density and bioluminescence intensity were correlated when bioluminescence levels were higher than 10^4 p/s/cm²/sr, corresponding to about 10^2 RED BSF or RED PCF parasites, allowing estimation of the parasite density from *in vivo* imaging over this threshold (Fig. 5C). In parallel, this linear correlation was verified in a TECAN multiwell-plate reader for several RED sub-clones of both parasite stages (Fig. 5D-E), yet with some bioluminescence intensity level variations between clones, especially for RED PCF. Second, the fluorescent signal emitted by these RED *T. brucei* parasites was measured in a IVIS fluorescence reader and appeared to be correlated to their number in a dynamic range starting from 10^3 PCF and 10^4 BSF (Fig. 5F-G), although the overall fluorescence intensity level in RED BSF was much lower compared to that in RED PCF (Fig. 5H). This is possibly due to the existence of BSF-specific chemical conditions in the cytosol, such as pH variations and / or high localized concentrations of cations, that may affect tdTomato activity, or to a higher photobleaching rate at 37°C, rather than to a lower turn-over or to a reduced folding efficiency, since the luciferase activity was not affected, as assessed by high bioluminescence levels. This observation was further confirmed by testing several subclones of both stages in a plate reader (Fig. 5I-J).

3.3 *In vivo* uses of RED *T. brucei* parasites

To test whether RED trypanosomes could be monitored *in vivo* in their insect vector, *Glossina morsitans morsitans* teneral males were experimentally infected with RED PCF parasites through a silicone membrane. One month after the infective meal, flies were screened under an epifluorescence binocular microscope for the presence of a specific red fluorescence through their abdominal cuticle, reflecting the presence of RED parasites in their midgut (Fig. 6A-B). To assess the stability of the triple reporter expression during the course of the infectious process, i.e. without any selective antibiotic pressure, both negative and positive flies were dissected and the presence of parasites in their midgut was verified by both light and epifluorescence microscope examination at a higher magnification (Fig. 6C-E). Living parasites were only detected in flies that were initially scored positive by fluorescence examination of the intact abdomen, demonstrating the stability of the triple reporter *in vivo* (Fig. 6F and Movie1). It is noteworthy that the red fluorescent component of the triple reporter could also be used to directly scrutinize the parasite development, motility and interactions *in vivo* or *ex vivo* within the tsetse host tissues and organs (Fig. 6E-F and Movie1) (Schuster et al., 2017). Then, in order to assess the virulence of RED parasites in the tsetse fly, a total of 17 batches of flies were fed with either WT BSF, WT PCF, RED BSF or RED PCF parasites in culture. Experimental infections were performed over a one-year period by comparing strains at least two by two. In total, 606 flies were dissected after one

month, and the infection rates in the midgut and salivary glands were compared between groups (Fig. 6G). For WT parasites, fly infection by BSF gave rise to significantly higher infection rates, especially in the midgut ($p=0.019$, ANOVA's Tukey ad-hoc post-test, 95% confidence). In total, RED parasites produced similar infection rates as compared to WT controls, except for the RED BSF that were significantly less prone than WT BSF to produce mature infection in the salivary glands ($p=0.003$, ANOVA's Tukey ad-hoc post-test, 95% confidence).

Conveniently, the possibility of assessing the infection by a simple observation of living flies allowed us to anticipate the number of flies which could be potentially infected at the salivary gland level. Therefore, in another experiment, only fluorescent flies were used for salivation tests one month after the infective meal in order to sort living tsetse flies with a mature salivary gland infection for further natural transmission experiments. Single flies with salivary gland infection were then used to naturally infect mice, and the course of the infection was monitored daily by acquiring the bioluminescent signal emitted by the parasites in the entire organism with an IVIS Spectrum imager (Fig. 7A). Mice bitten by uninfected flies and not bitten at all were used as controls. The parasitemia was also daily quantified by detecting RED fluorescent BSF in 5 μ l blood samples with a Muse bench flow-cytometer. In parallel, the parasitemia was verified by manual counting of living parasites with a KOVA hemocytometer (Fig. 7B). Similar parasitemia quantifications were obtained by both methods (not shown), demonstrating that the fluorescence, although being limited in RED BSF as compared to RED PCF, was stably maintained over the course of the infection. A significant bioluminescent signal was detected as soon as after 1 to 2 days and was persisting until the end of the experiment, whereas the parasitemia was only first detected after 17 days and further fluctuated by characteristic waves (Fig. 7C). This demonstrates that a substantial population of parasites remained extravascular during the entire course of the infection. As assessed by ventral and dorsal bioluminescence imaging, both the parasite distribution and density evolved in space and time during the entire infection course (Fig. 7C). This experiment reproduces our previous study where the bioluminescent signal intensity was used for quantifying the correlated parasite densities (Capewell et al., 2016). In the latter study, mice infected with RED BSF were sacrificed and dissected to record the bioluminescent signal in isolated organs: in contrast to the bioluminescent signals detected in the spleen, the liver, the inguinal and cervical lymph nodes and some adipose tissues, the skin was found to constitute the major anatomical reservoir of parasites even in the absence of detectable parasites in the blood (Capewell et al., 2016). Alternatively, in order to study the differential anatomical distribution of the RED parasites in living mice, we attempted to test longitudinal imaging with the IVIS Spectrum CT imager. The computed tomography application allowed us to extract the spatial 3D-localization of RED parasites, although only

in heavily infected organs (spleen, liver and lymph nodes) (Fig. 7D). To refine the observation of living parasites developing in the skin at the cell level, the same naturally-transmitted RED trypanosomes were also imaged *in vivo* using a spinning-disk confocal microscopy setting in the C57BL/6J-Flk1-EGFP mouse line that present green fluorescent endothelial cells in the lymphatic and blood vessels (Ema et al., 2006). Strikingly, extravascular trypanosomes were observed gliding and dividing in the dermal layer of the ear (Fig. S3B) (Capewell et al., 2016).

In total, the RED trypanosomes were comparable to the parental WT strain in terms of pleomorphism and tsetse infectivity. Both red markers were stably expressed in all stages of the parasite cycle, both *in vivo* and *in vitro*, in cells kept from 27°C to 37°C, in the absence of any antibiotic pressure, and over at least 3 months in total. All these features allowed us to scrutinize the kinetics of the same infection at different scales *in vivo* (single cells, tissue level and whole body).

3.4 Immuno-detection of the triple reporter construct with the TY1 tag

The bioluminescent and fluorescent properties of the two reporter proteins used in the construct mainly rely on their conformation and on the physico-chemical nature of the micro-environment. For this reason, common regular protocols, such as for electron microscopy, histology or protein biochemistry are known to at least partially alter protein structures, which results in a loss of enzymatic activity, fluorescence emission or immune-specificity. For these reasons, we have introduced the small Ty1-tag between the red-shifted luciferase and the tdTomato in order to stabilize the fusion protein and to serve as a third reporter in specific conditions where the two other reporters would not be detected. The Ty1-tag can be recognized by two different monoclonal antibodies with overlapping binding sites: BB2, which is an immunoglobulin G (IgG1) and TYG5, which is an immunoglobulin A.

The expression and accessibility of the Ty1 epitope was first assessed by immunofluorescence staining with BB2 in both RED *T. brucei* PCF (Fig. 8A) and RED *L. major* promastigotes (Fig. 8B) after a 5-seconds methanol fixation. The homogenous distribution of the signal within the entire cytoplasm and flagellum was similar to that obtained directly by recording the tdTomato emission in living cells (Fig.1B and 4B). Then, we performed a western blot in denaturing conditions in order to test the ability of BB2 to detect the Ty1 reporter in total protein samples from RED *T. brucei* PCF and RED *L. major* promastigote parasites (Fig. 8C). Different amounts of parasites (10^6 , 10^5 and 10^4) were tested in order to confirm the correlation between the total amount of proteins and the detection of the tag. A specific band of 110 kDa was revealed only in the protein samples from 10^5 and 10^6 transformed parasites. Finally, highly bioluminescent regions of the skin of naturally infected mice (Fig. 7A) were sampled, fixed in paraformaldehyde, paraffin-

embedded and treated for immuno-histological analysis with BB2. Although no direct red fluorescence was detected, probably as the result of the sample heating for paraffin-embedding, the BB2 antibody was able to *in situ* label skin-dwelling-parasites expressing the Ty1 tag (Fig. 8D). These results confirm the potential use of the Ty1-tag included in the chimeric triple reporter fusion protein in a wide variety of immunological assays pre-requiring chemical denaturation and / or heating of the samples.

4 Discussion and conclusion

4.1 Importance of intravital imaging in research on trypanosomatids

Intravital imaging approaches already led to important discoveries on the biology of trypanosomatid parasites. The use of bioluminescent *T. brucei* parasites has successively enable different research groups to identify specific anatomical niches that strongly support the preponderance of extravascular parasite populations during the infectious process. Claes and co-workers showed that parasites located in the testis were not cleared by trypanocidal drugs, as they were protected by the blood-testis barrier (Claes et al., 2009). Trindade *et al.* and Caljon *et al.* further observed a close association of *T. b. brucei* with adipocytes in fat tissues and subcutaneous adipose layers, respectively (Caljon et al., 2016; Trindade et al., 2016). At the same time, together with colleagues from Glasgow, Conakry and Kinshasa, we have demonstrated that the majority of *T. b. gambiense* parasites were actually rather developing in the extravascular matrix of the dermis of murine models, where they were seen actively swimming and dividing (Capewell et al., 2016). In another study by D'Archivio and co-workers, the importance of the late brain invasion by *T. vivax* parasites was assessed in a dynamic manner by intravital imaging of a bioluminescent strain (D'Archivio et al., 2013). Recently, the principal clinical, immunological and parasitological features associated with visceral leishmaniasis were characterized by *in vivo* imaging approaches of *L. donovani* transgenic parasites in a golden hamster model (Rouault et al., 2017) and the occurrence of multiple phases of brain invasion and inflammation was further unambiguously demonstrated (Melo et al., 2017). Bioluminescence has also been recently used to monitor the evolution of the *T. cruzi* parasite load in the digestive tract of its triatomine vector *Rhodnius prolixus* (Dias Fde et al., 2015).

Applied to drug development in high-throughput (HTS) *in vitro* assays as well as in *in vivo* murine models, bioluminescent and fluorescent trypanosomatid reporter strains have also proved their usefulness. Intravital multi-photon microscopy revealed that diminazene was unable to target *T. b. brucei* parasites that have already crossed the blood-brain barrier three weeks after the infection in a mouse model of stage 2 sleeping sickness (Myburgh et al., 2013). Reimão and co-workers evaluated the efficacy of miltefosine *in vivo* in a luciferase-

expressing *L. infantum chagasi* experimental model of infection in hamsters that mimics human disease (Reimao et al., 2015). A non-invasive model of lesion suppression has been recently validated for the semi-HTS screening of compounds against cutaneous leishmaniasis by using a bioluminescent strain of *L. major* (Caridha et al., 2017). Other studies have taken advantage of the use of fluorescent and / or bioluminescent parasites to screen myriads of compounds in multi-well plates. Annang and co-workers validated a HTS platform to screen a subset of microbial extracts against the 3 trypanosomatid-borne diseases in 384-well plates by using, among them, bioluminescent-*L. donovani* parasites (Annang et al., 2015). The use of *ex vivo* cultures from infected tissues or organs has been explored and exploited as well by some other research groups with bioluminescent *L. donovani* (Osorio et al., 2011) and *L. major* (Peniche et al., 2014), as well as with infrared-emitting *L. infantum* parasites (Calvo-Alvarez et al., 2015b).

4.2 Novel perspectives offered by the triple reporter

Most of these studies are relying on the use of constructs encoding for single green fluorescent probes or single luciferases emitting in the green. This is not optimal for intravital imaging due to the high absorption of the light by the tissue components at these wavelengths, and this also limits the monitoring to a single scale, i.e. whole organism or tissue / cell level. To bypass this technical bias, we have simultaneously used two reporters stably producing light in the red wavelengths with a reduced absorption by tissues, resulted in an enhanced sensitivity of the monitoring, with equivalent detection thresholds compared to previous studies (Burrell-Saward et al., 2015; McLatchie et al., 2013; Taheri et al., 2015; Van Reet et al., 2014). In the present study, as in the one of McLatchie and colleagues (McLatchie et al., 2013), we used a human codon optimized *PpyRE9h* sequence that was adapted to *T. brucei*. However, although this would theoretically have not been optimal for *Leishmania*, whose genome are more GC-rich, our results demonstrate that this actually doesn't seem to affect the triple marker expression. Taheri and collaborators have monitored and tracked a cutaneous *Leishmania* infection in real time, by generating stably-transgenic *L. major* parasites that expressed a bi-reporter protein constituted by an EGFP fused to a firefly luciferase. They demonstrated that the simultaneous use of two reporters increases the experimental sensitivity for detection and quantification of parasites *in vitro* as well as during real-time infection in mice (Taheri et al., 2015). In the present work, the constitutive cytosolic expression of the red triple reporter in African trypanosome and *Leishmania* strains in mice allowed us to study the kinetics of the infection in the same animal and at different scales by successively using a combination of complementary imaging technologies. We have demonstrated the correct expression of the transgenic constructs with a clear correlation between the number of parasites and the bioluminescent / fluorescent signals *in vitro*, thus

597 permitting the estimation of the parasite load by means of signal acquisition. However, using
598 this methodology for an exact *in vivo* quantification of the parasite densities in experimental
599 host tissues will further require a higher degree of standardization and some more controls in
600 order to obtain reliable and reproducible quantitative results. In total, the use of this triple
601 reporter led us to access both qualitative and quantitative data on the development of RED *L.*
602 *major* in a mouse model, as well as on the full parasite cycle of RED *T. brucei* in the tsetse
603 digestive tract and in the mammalian host after natural transmission. Furthermore, the Ty1-
604 tag was also used to refine the analysis of the same biological material after intravital
605 imaging, by immuno-based approaches (western blot, immunofluorescence analyses,
606 immunohistochemistry).

607 It was the powerful combination of both fluorescence and bioluminescence imaging that
608 allowed us to recently formally prove that skin-dwelling parasites were readily ingested by
609 tsetse flies to fulfil their parasite cycle (Capewell et al., 2016). In the context of other HAT
610 research projects, the optimised triple reporter line described here would also possibly
611 enhance the application of *in vivo* imaging to study stage II African trypanosomiasis in murine
612 models. Indeed, it will provide a new framework for investigating host-parasite relationships,
613 particularly in the context of CNS infections. In addition, it should be ideally suited to drug
614 evaluation programmes. This RED triple reporter construct represents a powerful tool that
615 could also be useful in many other fields of research where cellular model can be
616 transformed. According to the plasmid vector used and to its way of integration, the signal
617 intensities could theoretically be modulated. Moreover, although the size of the triple reporter
618 is not exactly appropriated, one could think about its potential use for protein tagging.
619 Possible simultaneous qualitative and quantitative applications in research are the use of its
620 bioluminescence component for *in vitro* HTS drugs screening and *in vivo* monitoring
621 (microbiology, immunology, parasitology, oncology, pharmacology, vaccinology...), the use
622 of its fluorescence for *in vitro* assays (HTS drug screening, investigation of biological
623 processes...) and *in vivo* monitoring (microbiology, immunology, parasitology, oncology...),
624 and the use of the Ty1-tag for immuno-detection in fixed and treated samples after real-time
625 intravital imaging.

627 **Conflict of interest statement**

628 The authors declare that the research was conducted in the absence of any commercial or
629 financial relationships that could be construed as a potential conflict of interest.

630 **Author contribution statement**

631 ECA, CCT and AC contributed to the experiments.

632 ECA and BR contributed to study design, data analysis and manuscript writing.

633 **Funding statement**

634 This work was funded by the Institut Pasteur (PTR-403), by a French Government
635 Investissement d'Avenir programme, Laboratoire d'Excellence "Integrative Biology of
636 Emerging Infectious Diseases" (ANR-10-LABX-62-IBEID) and by the French National
637 Agency for Scientific Research (Young Researcher Grant ANR-14-CE14-0019-01). ECA and
638 CCT were funded by a French Government Investissement d'Avenir programme, Laboratoire
639 d'Excellence "Integrative Biology of Emerging Infectious Diseases" (ANR-10-LABX-62-IBEID)
640 and by the French National Agency for Scientific Research (Young Researcher Grant ANR-
641 14-CE14-0019-01). AC and BR were funded by the Institut Pasteur.

642 **Acknowledgements**

643 We acknowledge Pascal Pescher and Gerald Späth, Keith Gull, Martin Taylor and Bruce
644 Branchini for providing various reagents. We are grateful to Philippe Bastin for his strong
645 human and scientific support. We especially thank Marie-Anne Nicola and Jean-Yves
646 Tinevez from the Dynamic Imaging Platform, Imagopole, CiTech, at the Institut Pasteur, for
647 their very efficient support in intravital imaging.

Figure legends

Fig. 1: Fluorescence pattern and growth of the RED *L. major*.

(A-B) Live epifluorescence microscopy images of a WT *L. major* promastigote (A) and a RED *L. major* promastigote (B) (normalized TdTomato fluorescence in red and DNA staining in blue). (C-D) Ungated flow-cytometry analysis profiles confirming the non-fluorescence and red fluorescence (in arbitrary units) of WT (C) and RED (D) *L. major* promastigote populations, respectively. (E) Growth profiles (mean $\pm$ SD from triplicates) of RED *L. major* promastigotes (in red) compared to their parental WT strain (in blue).

Fig. 2: Quantification of the RED *L. major* bioluminescence and fluorescence.

Images of the bioluminescent (A) and fluorescent (D) signals emitted by serial 1/2 dilutions of RED *L. major* promastigotes observed with an IVIS Spectrum in a 96-well plate. The same analysis was performed in triplicates for the RED strain (lines RED 1 to RED3). An equivalent serial dilution of WT promastigotes was used as control (line WT). The last three wells containing only medium were used as blank (red square). Radiance intensity scales are provided in p/s/cm²/sr on the right of each picture. (B, E) The mean bioluminescent (B) and fluorescent (E) signals ($\pm$ SD) emitted by RED promastigotes show a significant linear correlation with the number of cells (linear regression analysis; $r^2=1.0$ with $p<0.0001$ for BL; $r^2=0.99$ with $p<0.0001$ for fluorescence). (C, F) Bioluminescent (C) and fluorescent (F) signals ($\pm$ SD) emitted by 5 different RED *L. major* clones were measured in triplicates with a TECAN plate reader and plotted in arbitrary units (AU) according to the parasite density. A similar linear correlation was observed for all sub-clones.

Fig. 3: *In vivo* imaging applications with the RED *L. major*.

(A-B) *In vivo* whole-body images of BALB/c mice, including 1 uninfected control (C) and 4 infected mice (1 to 4), acquired with an IVIS Spectrum imager. Bioluminescent (A) and fluorescent (B) signals acquired on the hind footpads 28 days post-infection. Radiance intensity scales are provided in p/s/cm²/sr under each picture. (C, D) Bioluminescent (C) and fluorescent (D) signals on the hind footpads were measured and plotted over the course of the infection. (E, F) RED *L. major* amastigotes residing in the popliteal draining lymph nodes of 2 mice dissected 4 weeks after inoculation emit bioluminescence (E) and fluorescence (F). Radiance intensity scales are provided in p/s/cm²/sr under each picture.

Fig. 4: Fluorescence pattern and growth of the RED *T. brucei* PCF and BSF stages.

(A-B and E-F) Live epifluorescence microscopy images of WT (A and E) and RED (B and F) *T. brucei* PCF (A-B) and BSF (E-F) (normalized TdTomato fluorescence in red and DNA staining in blue). (C-D and G-H) Ungated flow-cytometry analysis profiles confirming the non-

fluorescence and red fluorescence (in arbitrary unit) of WT (C and G) and RED (D and H) *T. brucei* PCF (C-D) and BSF (G-H) populations, respectively. (I-J) Growth profiles (mean $\pm$ SD from triplicates) of WT (in blue) and RED (in red) *T. brucei* PCF (I) and BSF (J).

Fig. 5: Bioluminescence and fluorescence quantification in the RED *T. brucei* PCF and BSF stages.

Images of the bioluminescent (A-B) and fluorescent (F-G) signals emitted by serial 1/2 dilutions of RED *T. b. brucei* PCF (A and F) and BSF (B and G) observed with an IVIS Spectrum in 96-well plates. The same analyses were performed in triplicates for the RED strains (lines RED 1 to RED3). An equivalent serial dilution of WT parasites was used as control (lines WT). The last three wells containing only medium were used as blank (red square). Radiance intensity scales are provided in p/s/cm²/sr on the right of each picture. (C and H) The mean bioluminescent (C) and fluorescent (H) signals ($\pm$ SD) emitted by RED PCF (in blue, linear regression analysis with $p < 0.0001$, $r^2 = 0.97$ for BL and $r^2 = 0.96$ for fluorescence) and RED BSF (in red, linear regression analysis with $p < 0.0001$, $r^2 = 0.87$ for BL and $r^2 = 0.97$ for fluorescence) show a significant linear correlation with the number of cells. (D-E and I-J) Bioluminescent (D-E) and fluorescent (I-J) signals ($\pm$ SD) emitted by 3 different RED *T. b. brucei* PCF sub-clones (D and I) and 4 different RED *T. b. brucei* BSF subclones (E and J) were measured in triplicates with a TECAN plate reader and plotted in arbitrary units (AU) according to the parasite density. A similar linear correlation was observed for all sub-clones.

Fig. 6: Imaging applications with the RED *T. brucei* in the tsetse fly host.

Glossina morsitans morsitans teneral males were fed with RED PCF and observed under an epifluorescence binocular microscope after one month in order to sort infected flies. A strong red fluorescent signal was observed through the ventral abdomen of infected flies (B) but not in non-infected flies (A). This was confirmed by dissection and observation of the fly midgut (C and D, respectively). Fluorescence was even detected dorsally in strongly infected flies (E), and individual RED parasites could be distinguished under the epifluorescence binocular microscope in and outside dissected midguts (F, still image from movie S1). (G) The virulence of RED parasites was assessed by feeding batches of tsetse flies with either WT BSF, WT PCF, RED BSF or RED PCF parasites resuspended in SDMG culture medium. The histogram shows the infection rates in the midgut and salivary glands observed one month post infection (* statistically significant difference between indicated groups with $p < 0.02$ by ANCOVA's Tukey ad-hoc post-test at 95% confidence).

Fig. 7: Imaging applications with the RED *T. brucei* in the mammalian host after natural transmission.

(A) *In vivo* whole-body images of C57BL/6J mice acquired with an IVIS Spectrum imager 8, 15 and 22 days after a tsetse fly bite, including one mouse bitten an infected tsetse fly (+), one bitten by a non-infected fly (-) and one non-bitten (0). Radiance intensity scales are provided in p/s/cm²/sr. (B) Live RED BSF in a blood sample from mouse + (DNA in blue). (C) Total ventral (blue squares) and dorsal (green triangles) bioluminescent signals (total radiance in p/s/cm²/sr) were measured, normalized to negative controls and plotted over the course of the infection together with the parasitemia (red dots) for mouse +. (D) Bioluminescence and anatomical 3D computed tomography images acquired by an IVIS Spectrum CT on a BALB/c mouse 29 days post-inoculation. The 3D reconstruction view on the right panel has been decomposed in pictures along 3 distinct plans showed on the left (coronal in red, sagittal in blue and transaxial in green).

Fig. 8: Detection of RED trypanosomatids with the Ty1-tag after sample alteration by specific treatments.

(A, B) Immunofluorescence images of methanol-fixed RED *T. brucei* PCF (A) and RED *L. major* promastigotes (B) stained with the BB2 antibody (Ty1 in red) and DAPI (DNA in blue). (C) Reactivity of the BB2 monoclonal antibody against the Ty1-tag epitope (110 kDa) by Western Blot analysis. The L8C4 anti-PFR2 antibody (69 kDa) was used as a loading control. Total protein extracts from 10⁶, 10⁵ and 10⁴ cells were used to compare the expression levels of the Ty1-tag in RED *T. brucei* procyclic forms and RED *L. major* compared to their respective WT control strains. Ladders (L) are provided on both sides of the blot with their respective size in kDa. (D) Immuno-histological analysis of a paraffin-embedded bioluminescent skin section from a mouse infected with RED *T. brucei*, *in situ* stained with the BB2 antibody (Ty-1 in red) and DAPI (DNA in blue). A skin-dwelling-parasite expressing the Ty1-tag situated in the extracellular matrix of the dermis is indicated with a white arrow.

Supplementary material

Fig. S1: The PpyRE9/TY1/tdTomato fusion protein.

(A) Schematic view of the protein regions (1,036 aa). (B) DNA sequence (3,111 bp).

Fig. S2: Detection of the *PpyRE9H/TY1/tdTomato*-encoding gene and integration strategies into genomic *RRNA* loci of *T. brucei* and *L. major*.

(A) PCR analysis for confirmation of the genomic presence of the triple reporter sequence (primers 1/2) and the specific antibiotic cassettes in RED *T. brucei* (primers 3/4) and RED *L. major* (primers 5/6) parasites. (B) The upper scheme shows the final structure of the 18S *RRNA* locus of *T. brucei* with the planned integration of the triple marker sequence. The bottom scheme represents the expected integration of the chimeric 3.1 Kb multiplex reporter protein PpyRE9H/TY1/tdTomato in the genome of *L. major*. PARP SL: procyclin splice site; bsd: blasticidin resistance cassette; utr1: 5' untranslated region of *aprt* gene; utr2: 1.4 kb intergenic region from *cam* operon; and utr3: 5' UTR of *dhfr-ts* gene; hyg: hygromycin B resistance cassette. Primers 1 and 2 amplify the 3.1 Kb region of the PpyRE9H-TY1-tdTomato sequence (1-GGAGGACGCCAAGAACATCAAG; 2-TTACTTGTACAGCTCGTCCATGC); primers 3 and 4 amplify the blasticidin antibiotic cassette (3-ATGGCCAAGCCTTTGTCTCAAG; 4-TTAGCCCTCCCACACATAACCAG); and primers 5 and 6 were used to amplify the hygromycin resistance cassette (5-ATGAAAAAGCCTGAACTCACCGC; 6-CTATTCCTTTGCCCTCGGACG).

Fig. S3: Further imaging applications with RED parasites to monitor host cell / parasite interactions at the cellular level.

(A) RED *L. major* intracellular amastigotes within BALB/c peritoneal macrophages after 72 h of incubation (DNA in blue and red fluorescent amastigotes in red). (B) Still-image from a spinning-disk confocal microscope movie showing extravascular RED *T. brucei* parasites (in red) in the surrounding of a vascular or lymphatic vessel (in green) in the ear dermis of a living C57BL/6J-Flk1-EGFP mouse 21 days after an infective bite.

Movie S1: RED *T. b. brucei* in the posterior midgut of a tsetse fly 7 days after the infective meal.

Living RED *T. b. brucei* procyclic parasites observed with a binocular epifluorescence microscope within the posterior midgut of an infected tsetse fly 7 days after the infectious meal. Red fluorescent parasites can be seen swimming outside the organ.

References

- Aksoy, S., Buscher, P., Lehane, M., Solano, P., Van Den Abbeele, J., 2017. Human African trypanosomiasis control: Achievements and challenges. *PLoS Negl Trop Dis* 11, e0005454.
- Alvar, J., Velez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., den Boer, M., Team, W.H.O.L.C., 2012. Leishmaniasis worldwide and global estimates of its incidence. *PLoS One* 7, e35671.
- Annang, F., Perez-Moreno, G., Garcia-Hernandez, R., Cordon-Obras, C., Martin, J., Tormo, J.R., Rodriguez, L., de Pedro, N., Gomez-Perez, V., Valente, M., Reyes, F., Genilloud, O., Vicente, F., Castanys, S., Ruiz-Perez, L.M., Navarro, M., Gamarro, F., Gonzalez-Pacanowska, D., 2015. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease. *J Biomol Screen* 20, 82-91.
- Barquilla, A., Saldivia, M., Diaz, R., Bart, J.M., Vidal, I., Calvo, E., Hall, M.N., Navarro, M., 2012. Third target of rapamycin complex negatively regulates development of quiescence in *Trypanosoma brucei*. *Proc Natl Acad Sci U S A* 109, 14399-14404.
- Bastin, P., Bagherzadeh, Z., Matthews, K.R., Gull, K., 1996. A novel epitope tag system to study protein targeting and organelle biogenesis in *Trypanosoma brucei*. *Mol Biochem Parasitol* 77, 235-239.
- Beattie, L., Kaye, P.M., 2011. Leishmania-host interactions: what has imaging taught us? *Cell Microbiol* 13, 1659-1667.
- Branchini, B.R., Southworth, T.L., Khattak, N.F., Michelini, E., Roda, A., 2005. Red- and green-emitting firefly luciferase mutants for bioluminescent reporter applications. *Anal Biochem* 345, 140-148.
- Brookman, J.L., Stott, A.J., Cheeseman, P.J., Burns, N.R., Adams, S.E., Kingsman, A.J., Gull, K., 1995. An immunological analysis of Ty1 virus-like particle structure. *Virology* 207, 59-67.
- Brun, R., Schonenberger, 1979. Cultivation and in vitro cloning of procyclic culture forms of *Trypanosoma brucei* in a semi-defined medium. Short communication. *Acta Trop* 36, 289-292.
- Burkard, G., Fragoso, C.M., Roditi, I., 2007. Highly efficient stable transformation of bloodstream forms of *Trypanosoma brucei*. *Mol Biochem Parasitol* 153, 220-223.
- Burrell-Saward, H., Rodgers, J., Bradley, B., Croft, S.L., Ward, T.H., 2015. A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis. *The Journal of antimicrobial chemotherapy* 70, 510-517.
- Buscher, P., Cecchi, G., Jamonneau, V., Priotto, G., 2017. Human African trypanosomiasis. *Lancet*.

809 Caljon, G., Van Reet, N., De Trez, C., Vermeersch, M., Perez-Morga, D., Van Den Abbeele,
810 J., 2016. The Dermis as a Delivery Site of *Trypanosoma brucei* for Tsetse Flies. *PLoS*
811 *Pathog* 12, e1005744.

812 Calvo-Alvarez, E., Alvarez-Velilla, R., Fernandez-Prada, C., Balana-Fouce, R., Reguera,
813 R.M., 2015a. Trypanosomatids see the light: recent advances in bioimaging research. *Drug*
814 *Discov Today* 20, 114-121.

815 Calvo-Alvarez, E., Stamatakis, K., Punzon, C., Alvarez-Velilla, R., Tejeria, A., Escudero-
816 Martinez, J.M., Perez-Pertejo, Y., Fresno, M., Balana-Fouce, R., Reguera, R.M., 2015b.
817 Infrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral
818 leishmaniasis. *PLoS Negl Trop Dis* 9, e0003666.

819 Capewell, P., Cren-Travaille, C., Marchesi, F., Johnston, P., Clucas, C., Benson, R.A.,
820 Gorman, T.A., Calvo-Alvarez, E., Crouzols, A., Jouvion, G., Jamonneau, V., Weir, W.,
821 Stevenson, M.L., O'Neill, K., Cooper, A., Swar, N.K., Bucheton, B., Ngoyi, D.M., Garside, P.,
822 Rotureau, B., MacLeod, A., 2016. The skin is a significant but overlooked anatomical
823 reservoir for vector-borne African trypanosomes. *eLife* 5.

824 Caridha, D., Parriot, S., Hudson, T.H., Lang, T., Ngundam, F., Leed, S., Sena, J., Harris, M.,
825 O'Neil, M., Sciotti, R., Read, L., Lecoecur, H., Hickman, M., Grogl, M., 2017. Use of Optical
826 Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of
827 a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous
828 Leishmaniasis. *Antimicrob Agents Chemother* 61.

829 Carneiro, M.B., Hohman, L.S., Egen, J.G., Peters, N.C., 2017. Use of two-photon microscopy
830 to study *Leishmania major* infection of the skin. *Methods*.

831 Claes, F., Vodnala, S.K., van Reet, N., Boucher, N., Lunden-Miguel, H., Baltz, T., Goddeeris,
832 B.M., Buscher, P., Rottenberg, M.E., 2009. Bioluminescent imaging of *Trypanosoma brucei*
833 shows preferential testis dissemination which may hamper drug efficacy in sleeping sickness.
834 *PLoS Negl Trop Dis* 3, e486.

835 Coles, J.A., Stewart-Hutchinson, P.J., Myburgh, E., Brewer, J.M., 2017. The mouse cortical
836 meninges are the site of immune responses to many different pathogens, and are accessible
837 to intravital imaging. *Methods*.

838 Coombes, J.L., Robey, E.A., 2010. Dynamic imaging of host-pathogen interactions in vivo.
839 *Nat Rev Immunol* 10, 353-364.

840 D'Archivio, S., Cosson, A., Medina, M., Lang, T., Minoprio, P., Goyard, S., 2013. Non-
841 invasive in vivo study of the *Trypanosoma vivax* infectious process consolidates the brain
842 commitment in late infections. *PLoS Negl Trop Dis* 7, e1976.

843 Dias Fde, A., Guerra, B., Vieira, L.R., Perdomo, H.D., Gandara, A.C., Amaral, R.J., Vollu,
844 R.E., Gomes, S.A., Lara, F.A., Sorgine, M.H., Medei, E., de Oliveira, P.L., Salmon, D., 2015.
845 Monitoring of the Parasite Load in the Digestive Tract of *Rhodnius prolixus* by Combined

846 qPCR Analysis and Imaging Techniques Provides New Insights into the Trypanosome Life
847 Cycle. *PLoS Negl Trop Dis* 9, e0004186.

848 Dias, J.C., 2015. Evolution of Chagas disease screening programs and control programs:
849 historical perspective. *Glob Heart* 10, 193-202.

850 Ema, M., Takahashi, S., Rossant, J., 2006. Deletion of the selection cassette, but not cis-
851 acting elements, in targeted Flk1-lacZ allele reveals Flk1 expression in multipotent
852 mesodermal progenitors. *Blood* 107, 111-117.

853 Forestier, C.L., 2013. Imaging host-Leishmania interactions: significance in visceral
854 leishmaniasis. *Parasite Immunol* 35, 256-266.

855 Franco, J.R., Cecchi, G., Priotto, G., Paone, M., Diarra, A., Grout, L., Mattioli, R.C., Argaw,
856 D., 2017. Monitoring the elimination of human African trypanosomiasis: Update to 2014.
857 *PLoS Negl Trop Dis* 11, e0005585.

858 Gonzalez, U., Pinart, M., Sinclair, D., Firooz, A., Enk, C., Velez, I.D., Esterhuizen, T.M.,
859 Tristan, M., Alvar, J., 2015. Vector and reservoir control for preventing leishmaniasis.
860 *Cochrane Database Syst Rev*, CD008736.

861 Huet, D., Blisnick, T., Perrot, S., Bastin, P., 2014. The GTPase IFT27 is involved in both
862 anterograde and retrograde intraflagellar transport. *eLife* 3, e02419.

863 Julkowska, D., Bastin, P., 2009. Tools for analyzing intraflagellar transport in trypanosomes.
864 *Methods Cell Biol* 93, 59-80.

865 Kapler, G.M., Zhang, K., Beverley, S.M., 1990. Nuclease mapping and DNA sequence
866 analysis of transcripts from the dihydrofolate reductase-thymidylate synthase (R) region of
867 *Leishmania major*. *Nucleic Acids Res* 18, 6399-6408.

868 Kohl, L., Sherwin, T., Gull, K., 1999. Assembly of the paraflagellar rod and the flagellum
869 attachment zone complex during the *Trypanosoma brucei* cell cycle. *J Eukaryot Microbiol* 46,
870 105-109.

871 Kooy, R.F., Hirumi, H., Moloo, S.K., Nantulya, V.M., Dukes, P., Van der Linden, P.M.,
872 Duijndam, W.A., Janse, C.J., Overdulve, J.P., 1989. Evidence for diploidy in metacyclic
873 forms of African trypanosomes. *Proc Natl Acad Sci U S A* 86, 5469-5472.

874 Lang, T., Lecoœur, H., Prina, E., 2009. Imaging *Leishmania* development in their host cells.
875 *Trends Parasitol* 25, 464-473.

876 Le Ray, D., Barry, J.D., Easton, C., Vickerman, K., 1977. First tsetse fly transmission of the
877 "AnTat" serodeme of *Trypanosoma brucei*. *Ann Soc Belg Med Trop* 57, 369-381.

878 Lewis, M.D., Francisco, A.F., Taylor, M.C., Kelly, J.M., 2015. A new experimental model for
879 assessing drug efficacy against *Trypanosoma cruzi* infection based on highly sensitive in
880 vivo imaging. *J Biomol Screen* 20, 36-43.

881 Lim, E., Modi, K., Christensen, A., Meganck, J., Oldfield, S., Zhang, N., 2011. Monitoring
882 tumor metastases and osteolytic lesions with bioluminescence and micro CT imaging. *J Vis*
883 *Exp*.

884 Lima, H.C., Bleyenbergh, J.A., Titus, R.G., 1997. A simple method for quantifying *Leishmania*
885 in tissues of infected animals. *Parasitol Today* 13, 80-82.

886 Liu, H., Patel, M.R., Prescher, J.A., Patsialou, A., Qian, D., Lin, J., Wen, S., Chang, Y.F.,
887 Bachmann, M.H., Shimono, Y., Dalerba, P., Adorno, M., Lobo, N., Bueno, J., Dirbas, F.M.,
888 Goswami, S., Somlo, G., Condeelis, J., Contag, C.H., Gambhir, S.S., Clarke, M.F., 2010.
889 Cancer stem cells from human breast tumors are involved in spontaneous metastases in
890 orthotopic mouse models. *Proc Natl Acad Sci U S A* 107, 18115-18120.

891 MacGregor, P., Rojas, F., Dean, S., Matthews, K.R., 2013. Stable transformation of
892 pleomorphic bloodstream form *Trypanosoma brucei*. *Mol Biochem Parasitol* 190, 60-62.

893 MacLean, L., Myburgh, E., Rodgers, J., Price, H.P., 2013. Imaging African trypanosomes.
894 *Parasite Immunol* 35, 283-294.

895 MacLeod, E.T., Maudlin, I., Darby, A.C., Welburn, S.C., 2007. Antioxidants promote
896 establishment of trypanosome infections in tsetse. *Parasitology* 134, 827-831.

897 Matlashewski, G., Arana, B., Kroeger, A., Be-Nazir, A., Mondal, D., Nabi, S.G., Banjara,
898 M.R., Das, M.L., Marasini, B., Das, P., Medley, G., Satoskar, A., Nakhasi, H., Argaw, D.,
899 Reeder, J., Oliaro, P., 2014. Research priorities for elimination of visceral leishmaniasis.
900 *Lancet Glob Health* 2, e683-684.

901 McLatchie, A.P., Burrell-Saward, H., Myburgh, E., Lewis, M.D., Ward, T.H., Mottram, J.C.,
902 Croft, S.L., Kelly, J.M., Taylor, M.C., 2013. Highly sensitive in vivo imaging of *Trypanosoma*
903 *brucei* expressing "red-shifted" luciferase. *PLoS Negl Trop Dis* 7, e2571.

904 Melo, G.D., Goyard, S., Fiette, L., Boissonnas, A., Combadiere, C., Machado, G.F., Minoprio,
905 P., Lang, T., 2017. Unveiling Cerebral Leishmaniasis: parasites and brain inflammation in
906 *Leishmania donovani* infected mice. *Sci Rep* 7, 8454.

907 Mezzanotte, L., Blankevoort, V., Lowik, C.W., Kaijzel, E.L., 2014. A novel luciferase fusion
908 protein for highly sensitive optical imaging: from single-cell analysis to in vivo whole-body
909 bioluminescence imaging. *Analytical and bioanalytical chemistry* 406, 5727-5734.

910 Myburgh, E., Coles, J.A., Ritchie, R., Kennedy, P.G., McLatchie, A.P., Rodgers, J., Taylor,
911 M.C., Barrett, M.P., Brewer, J.M., Mottram, J.C., 2013. In vivo imaging of trypanosome-brain
912 interactions and development of a rapid screening test for drugs against CNS stage
913 trypanosomiasis. *PLoS Negl Trop Dis* 7, e2384.

914 Ooi, C.P., Rotureau, B., Gribaldo, S., Georgikou, C., Julkowska, D., Blisnick, T., Perrot, S.,
915 Subota, I., Bastin, P., 2015. The Flagellar Arginine Kinase in *Trypanosoma brucei* Is
916 Important for Infection in Tsetse Flies. *PLoS ONE* 10, e0133676.

917 Osorio, Y., Travi, B.L., Renslo, A.R., Peniche, A.G., Melby, P.C., 2011. Identification of small
918 molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant
919 model system. *PLoS Negl Trop Dis* 5, e962.

920 Patel, M.R., Chang, Y.F., Chen, I.Y., Bachmann, M.H., Yan, X., Contag, C.H., Gambhir, S.S.,
 921 2010. Longitudinal, noninvasive imaging of T-cell effector function and proliferation in living
 922 subjects. *Cancer Res* 70, 10141-10149.

923 Peniche, A.G., Osorio, Y., Renslo, A.R., Frantz, D.E., Melby, P.C., Travi, B.L., 2014.
 924 Development of an ex vivo lymph node explant model for identification of novel molecules
 925 active against *Leishmania major*. *Antimicrob Agents Chemother* 58, 78-87.

926 Perez-Molina, J.A., Molina, I., 2017. Chagas disease. *Lancet*.

927 Reimao, J.Q., Oliveira, J.C., Trinconi, C.T., Cotrim, P.C., Coelho, A.C., Uliana, S.R., 2015.
 928 Generation of luciferase-expressing *Leishmania infantum chagasi* and assessment of
 929 miltefosine efficacy in infected hamsters through bioimaging. *PLoS Negl Trop Dis* 9,
 930 e0003556.

931 Reithinger, R., Dujardin, J.C., Louzir, H., Pirmez, C., Alexander, B., Brooker, S., 2007.
 932 Cutaneous leishmaniasis. *Lancet Infect Dis* 7, 581-596.

933 Rotureau, B., Ooi, C.P., Huet, D., Perrot, S., Bastin, P., 2014. Forward motility is essential for
 934 trypanosome infection in the tsetse fly. *Cell Microbiol* 16, 425-433.

935 Rotureau, B., Subota, I., Bastin, P., 2011. Molecular bases of cytoskeleton plasticity during
 936 the *Trypanosoma brucei* parasite cycle. *Cell Microbiol* 13, 705-716.

937 Rotureau, B., Subota, I., Buisson, J., Bastin, P., 2012. A new asymmetric division contributes
 938 to the continuous production of infective trypanosomes in the tsetse fly. *Development* 139,
 939 1842-1850.

940 Rotureau, B., Van Den Abbeele, J., 2013. Through the dark continent: African trypanosome
 941 development in the tsetse fly. *Frontiers in cellular and infection microbiology* 3, 53.

942 Rouault, E., Lecoœur, H., Meriem, A.B., Minoprio, P., Goyard, S., Lang, T., 2017. Imaging
 943 visceral leishmaniasis in real time with golden hamster model: Monitoring the parasite burden
 944 and hamster transcripts to further characterize the immunological responses of the host.
 945 *Parasitol Int* 66, 933-939.

946 Schuster, S., Kruger, T., Subota, I., Thusek, S., Rotureau, B., Beilhack, A., Engstler, M.,
 947 2017. Developmental adaptations of trypanosome motility to the tsetse fly host environments
 948 unravel a multifaceted in vivo microswimmer system. *eLife* 6.

949 Spath, G.F., Epstein, L., Leader, B., Singer, S.M., Avila, H.A., Turco, S.J., Beverley, S.M.,
 950 2000. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the
 951 protozoan parasite *Leishmania major*. *Proc Natl Acad Sci U S A* 97, 9258-9263.

952 Stanaway, J.D., Roth, G., 2015. The burden of Chagas disease: estimates and challenges.
 953 *Glob Heart* 10, 139-144.

954 Taheri, T., Saberi Nik, H., Seyed, N., Doustdari, F., Etemadzadeh, M.H., Torkashvand, F.,
 955 Rafati, S., 2015. Generation of stable *L. major*(+EGFP-LUC) and simultaneous comparison
 956 between EGFP and luciferase sensitivity. *Exp Parasitol* 150, 44-55.

957 Takai, A., Nakano, M., Saito, K., Haruno, R., Watanabe, T.M., Ohyanagi, T., Jin, T., Okada,
 958 Y., Nagai, T., 2015. Expanded palette of Nano-lanterns for real-time multicolor luminescence
 959 imaging. *Proc Natl Acad Sci U S A* 112, 4352-4356.
 960 Trindade, S., Rijo-Ferreira, F., Carvalho, T., Pinto-Neves, D., Guegan, F., Aresta-Branco, F.,
 961 Bento, F., Young, S.A., Pinto, A., Van Den Abbeele, J., Ribeiro, R.M., Dias, S., Smith, T.K.,
 962 Figueiredo, L.M., 2016. *Trypanosoma brucei* Parasites Occupy and Functionally Adapt to the
 963 Adipose Tissue in Mice. *Cell Host Microbe*.
 964 Van Reet, N., Van de Vyver, H., Pyana, P.P., Van der Linden, A.M., Buscher, P., 2014. A
 965 panel of *Trypanosoma brucei* strains tagged with blue and red-shifted luciferases for
 966 bioluminescent imaging in murine infection models. *PLoS Negl Trop Dis* 8, e3054.
 967 Willmann, J.K., van Bruggen, N., Dinkelborg, L.M., Gambhir, S.S., 2008. Molecular imaging
 968 in drug development. *Nat Rev Drug Discov* 7, 591-607.
 969 Xong, H.V., Vanhamme, L., Chamekh, M., Chimfwembe, C.E., Van Den Abbeele, J., Pays,
 970 A., Van Meirvenne, N., Hamers, R., De Baetselier, P., Pays, E., 1998. A VSG expression
 971 site-associated gene confers resistance to human serum in *Trypanosoma rhodesiense*. *Cell*
 972 95, 839-846.
 973

WT *L. major* **RED *L. major***

Bioluminescence

(Radiance in p/s/cm²/sr)

Fluorescence

(Radiance in p/s/cm²/sr)

WT *T. b. brucei*

RED *T. b. brucei*

PCF

BSF

In vivo imager

Bioluminescence
(Radiance in p/s/cm²/sr)

In vitro plate reader

Fluorescence
(Radiance in p/s/cm²/sr)

- RED parasites

+ RED parasites

G

A

B

C

D

A

B

ATGGAGGACGCCAAGAACATCAAGAAGGGACCAGCCCCCTTCTACCCCTGGAGGACGGCACAGCCGGCGAGCAGCTGCA
CAAGGCCATGAAGCGGTACGCCCTGGTGCCAGGCACCATCGCCTTCACCGACGCCACATCGAGGTGAACATCACCTACG
CCGAGTACTTCGAGATGAGCGTGCGGCTGGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTG
TGCAGCGAGAACAGCCTGCAGTTCTTCATGCCCGTGCTGGGAGCCCTGTTTCATCGGCGTGGCCGTGGCCCCAGCCAACGA
CATCTACAACGAGCGGGAGCTGCTGAACAGCATGAACATCAGCCAGCCACCCTGGTGTTCGTGAGCAAGAAGGGCCTGC
AGAAGATCCTGAATGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGATTACCAGGGC
TTCCAGAGCATGTACACCTTCGTGACCAGCCACCTGCCCCAGGCTTCAACGAGTACGACTTCGTGCCCGAGAGCTTCGA
CCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGCCTGCCAAGGGCGTGGCCCTGCCCCACCGGG
CCCTGTGCGTGCGGTTTCAGCCACGCCAGAGACCCCATCTTCGGCAACCAGATCGCCCCGACACCGCCATCCTGAGCGTG
GTGCCCTTCACCACGGCTTCGGCATGTTACCCACCTGGGCTACCTGATCTGCGGCTTCGGGTGGTGCTGATGTACAG
GTTTCGAGGAGGAGCTGTTCTTCGCGAGCCTGCAGGACTACAAGATCCAGACCGCCCTGCTGGTGCCACCCCTGTTACGT
TCCTGGCCAAGAGCACCCCTGATCGACAAGTACGACCTGAGCAACCTGCACGAGATCGCCTCTGGCGGAGCCCCACTGAGC
AAGGAGGTGGGCGAGGGCTGGCCAAGGGCTTCACCTGCCAGGCATCCGGCAGGGCTACGGCCTGACCGAGACCACCAG
CGCCATCCTGGTGACCCCCATCGGCGACGACAAGCCCGAGCCGTGGGCAAGGTGGTGCCCTTCTTCGAGGCCAAGGTGG
TGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCAGAGAGGCGAGCTGTGCGTGAGAGGCCCCATGATCATGAGCGGC
TACGTGAACAACCCCGAGGGCCACCAACGCCCTGATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGA
CGAGGACGAGCACTTCTTCATCGTGACCGGCTGAAGAGCCTGATCAAGTACAAGGGCTACCAGGTGGCCCCAGCCGAGC
TGGAGAGCATCCTGCTGCAGCACCCCAACATCCGGGACGCCGAGTGGCCGGAAGTGGCCGACGACGACGCCGAGAGCTG
CCAGCCGCCGTGGTGGTGCTGGAGCACGGCAAGACCATGACCGAGAAGGAGATCGTGGACTACGTGGCCAGCCAGGTGAC
CACCGCCAAGAAGCTGAGAGGCGGCGTGGTGTTCTGGACGAGGTGCCAAGGGCCTGACCGGCAAGCTGGACGCCAGAA
AGATCCGGGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCGAGGTCCATACTAACCAGGACCCACTTGACaagctt
ATGGTGAGCAAGGGCGAGGAGGTTCATCAAAGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCATGAACGGCCACGA
GTTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGCC
CCCTGCCCTTCGCTGGGACATCCTGTCCCCCAGTTCATGTACGGCTCCAAGGCGTACGTGAAGCACCCCGCCGACATC
CCCGATTACAAGAAGCTGTCTTCCCGAGGGCTTCAAGTGGGAGCGCGTATGAACCTTCGAGGACGGCGGTCTGGTGAC
CGTGACCCAGGACTCCTCCCTGCAGGACGGCACGCTGATCTACAAGGTGAAGATGCGCGGCACCAACTTCCCCCCGACG
GCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCGCGACGGCGTGCTGAAGGGC
GAGATCCACCAGGCCTGAAGCTGAAGGACGGCGGCCACTACCTGGTGGAGTTCAAGACCATCTACATGGCCAAGAAGCC
CGTGCAACTGCCCGGCTACTACTACGTGGACACCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAAC
AGTACGAGCGCTCCGAGGGCCGCCACCACCTGTTCTGGGGCATGGCACCAGGACCGGCAGCGGCAGCTCCGGCACC
GCCTCCTCCGAGGACAACAACATGGCCGTATCAAAGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCATGAACGG
CCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGG
GCGGCCCCCTGCCCTTCGCTGGGACATCCTGTCCCCCAGTTCATGTACGGCTCCAAGGCGTACGTGAAGCACCCCGCC
GACATCCCCGATTACAAGAAGCTGTCTTCCCGAGGGCTTCAAGTGGGAGCGCGTATGAACCTTCGAGGACGGCGGTCT
GGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCACGCTGATCTACAAGGTGAAGATGCGCGGCACCAACTTCCCCC
CCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCGCGACGGCGTGCTG
AAGGGCGAGATCCACCAGGCCCTGAAGCTGAAGGACGGCGGCCACTACCTGGTGGAGTTCAAGACCATCTACATGGCCAA
GAAGCCCGTGCAACTGCCCGGCTACTACTACGTGGACACCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCG
TGGAACAGTACGAGCGCTCCGAGGGCCGCCACCACCTGTTCTGTACGGCATGGACGAGCTGTACAAGTAA

A **B**

A

DNA
RED *Leishmania*

DNA
RED *Leishmania*

B

Endothelial cells (EGFP)
Trypanosomes (TdTomato)